AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 175 filers reported holding AMYLYX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $148,000 | +68.2% | 8,095 | +98.7% | 0.00% | – |
| Q2 2023 | $88,000 | -17.8% | 4,074 | +12.3% | 0.00% | – |
| Q1 2023 | $107,000 | -56.7% | 3,628 | -45.7% | 0.00% | – |
| Q4 2022 | $247,000 | +550.0% | 6,677 | +386.3% | 0.00% | – |
| Q3 2022 | $38,000 | +100.0% | 1,373 | +36.2% | 0.00% | – |
| Q2 2022 | $19,000 | -66.1% | 1,008 | -76.5% | 0.00% | – |
| Q1 2022 | $56,000 | – | 4,294 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 2,515,868 | $46,065,543 | 15.30% |
| Alpha Wave Global, LP | 853,262 | $15,623,227 | 9.88% |
| Saturn V Capital Management LP | 886,143 | $16,225,278 | 6.79% |
| Ally Bridge Group (NY) LLC | 272,690 | $4,992,954 | 5.86% |
| Altium Capital Management LP | 534,700 | $9,790,357 | 5.11% |
| Boxer Capital, LLC | 2,084,000 | $38,158,040 | 2.03% |
| Octagon Capital Advisors LP | 695,000 | $12,725,450 | 1.96% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 295,000 | $5,398,500 | 1.82% |
| Tri Locum Partners LP | 282,862 | $5,179,203 | 1.66% |
| Perceptive Advisors | 2,688,873 | $49,233,265 | 1.64% |